Clearside Deferred Long Term Liab from 2010 to 2024
| CLSD Stock | USD 1.08 0.06 5.88% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 544.5 K | Current Value 588 K | Quarterly Volatility 600.4 K |
Check Clearside Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearside Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.5 K, Interest Expense of 9.8 M or Other Operating Expenses of 35.5 M, as well as many indicators such as Price To Sales Ratio of 8.35, Dividend Yield of 0.0 or Days Sales Outstanding of 8.24. Clearside financial statements analysis is a perfect complement when working with Clearside Biomedical Valuation or Volatility modules.
Clearside | Deferred Long Term Liab |
Latest Clearside Biomedical's Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Clearside Biomedical over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Clearside Biomedical's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearside Biomedical's overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Clearside Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 948,500 | |
| Geometric Mean | 772,836 | |
| Coefficient Of Variation | 63.30 | |
| Mean Deviation | 534,333 | |
| Median | 605,000 | |
| Standard Deviation | 600,373 | |
| Sample Variance | 360.4B | |
| Range | 1.6M | |
| R-Value | (0.75) | |
| Mean Square Error | 168.6B | |
| R-Squared | 0.57 | |
| Significance | 0 | |
| Slope | (100,971) | |
| Total Sum of Squares | 5T |
Clearside Deferred Long Term Liab History
About Clearside Biomedical Financial Statements
Clearside Biomedical stakeholders use historical fundamental indicators, such as Clearside Biomedical's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Although Clearside Biomedical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Clearside Biomedical's assets and liabilities are reflected in the revenues and expenses on Clearside Biomedical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Clearside Biomedical. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 544.5 K | 588 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Clearside Biomedical is a strong investment it is important to analyze Clearside Biomedical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Clearside Biomedical's future performance. For an informed investment choice regarding Clearside Stock, refer to the following important reports:Check out the analysis of Clearside Biomedical Correlation against competitors. For information on how to trade Clearside Stock refer to our How to Trade Clearside Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Clearside Biomedical. If investors know Clearside will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Clearside Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.91) | Return On Assets (0.44) | Return On Equity (13.10) |
The market value of Clearside Biomedical is measured differently than its book value, which is the value of Clearside that is recorded on the company's balance sheet. Investors also form their own opinion of Clearside Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Clearside Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Clearside Biomedical's market value can be influenced by many factors that don't directly affect Clearside Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Clearside Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Clearside Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Clearside Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.